IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival
The IMpower150 trial (NCT02366143) was the first to explore chemotherapy, immunotherapy with atezolizumab and anti-angiogenic therapy with bevacizumab for non-small cell lung cancer (NSCLC). In this i...
Author: VJOncology
Added: 04/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer